CompletedEUCTR 2009-017523-26
A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Estonia and 6 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 600
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium, Estonia, Finland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2009-017523-26
- Official title
Show the full official title
A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Estonia · Finland
5 more locations
- Germany
- Latvia
- Lithuania
- Slovakia
- Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
